Study Design

Fractionated MYLOTARG demonstrated efficacy and tolerability as induction in first relapse1,2
MyloFrance-1 was a Phase 2, single-arm, open-label study evaluating MYLOTARG in 57 adults with CD33-positive AML in first relapse1
  • Consolidation therapy consisted of cytarabine IV every 12 hours for 3 days at 3 g/m2 for patients less than 55 years old and 1 g/m2 for patients 55 years or older and/or with a creatinine clearance below 50 mL/min
  • Patients with secondary leukemia or a prior autologous or allogeneic stem cell transplantation were excluded
  • Hematopoietic stem cell transplantation (HSCT) was allowed after treatment with MYLOTARG, but an interval of at least 90 days between the last dose of MYLOTARG and HSCT was recommended
AML=acute myeloid leukemia; CR=complete remission.
1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.
2. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66-71.